Tin tức & Cập nhật
Xem bài viết Dược
Xem
1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL
The final results of the CLL14 trial validate the long-term efficacy of 1-year fixed-duration venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia (CLL) and co-existing conditions.
GARNET updates confirm long-term dostarlimab benefit in dMMR/MSI-H endometrial cancer
Updates from the GARNET trial underpin dostarlimab monotherapy as a meaningful treatment option for women with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) advanced/recurrent endometrial cancer (A/R EC) who progressed after prior platinum therapy.
Oral paclitaxel on par with IV formulation in HER2-negative breast cancer
A novel oral formulation of paclitaxel, DHP107, is noninferior to weekly intravenous (IV) paclitaxel in the treatment of HER2-negative recurrent or metastatic breast cancer, as shown by the results of the phase III OPTIMAL study.
MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM
In the phase III MonumenTAL-3 trial, talquetamab plus daratumumab (Tal-D), with or without pomalidomide, shows substantial efficacy in the treatment of relapsed/refractory multiple myeloma (RRMM), compared with daratumumab, pomalidomide, and dexamethasone (DPd).
Triple win for fixed-dose combo in T2D
A fixed-dose combination of the novel amylin receptor agonist cagrilintide and the approved GLP-1 receptor agonist semaglutide (CagriSema) yields better HbA1c control and weight loss in patients with type 2 diabetes (T2D) than either therapy alone or placebo in three phase III trials from the global REIMAGINE programme presented at ADA 2026. The benefits also extend to patients on insulin therapy.
Pooled KARDIA data show effective BP control with add-on zilebesiran
A pooled analysis of data from the phase II KARDIA 2 and 3 studies shows the blood pressure (BP)-lowering potential of zilebesiran, an investigational, long-acting RNA interference therapeutic, when added to a renin–angiotensin–aldosterone system inhibitor (RAASi) in patients with hypertension (HTN).